Dapagliflozin in Living-Donor Kidney Transplant Recipients

This randomized, open-label, single-center clinical trial aims to evaluate the effect of dapagliflozin on kidney allograft function in adult recipients of a first living-donor kidney transplant. Participants will be randomized to receive dapagliflozin 10 mg daily starting 4 weeks after transplantation or standard care without SGLT2 inhibitor therapy. The primary outcomes include changes in estimated glomerular filtration rate (eGFR) and albuminuria over 12 months. Secondary outcomes include kidney graft histology findings, oxidative stress biomarkers, cardiovascular parameters, infectious events, and kidney graft survival at 12 months.

NCT Number	NCT07555106
Lead Sponsor	University of Guadalajara Collaborators: Instituto Mexicano del Seguro Social
Conditions	Kidney Transplant, Kidney Transplant Failure
Enrollment	54 participants
Start Date	2024-09-15
Primary Completion	2026-09-30 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-29